Last updated: October 25, 2026
LAMICTAL CD is the chewable/dispersible formulation of lamotrigine, originally commercialized by GlaxoSmithKline for epilepsy and bipolar disorder. Its commercial position is now mature and largely genericized. The product has no meaningful remaining U.S. patent or regulatory exclusivity, and GSK does not report standalone revenue for LAMICTAL CD. Financial value has shifted from branded product sales to a low-cost, high-volume lamotrigine market supplied by multiple generic manufacturers.
What is LAMICTAL CD and how is it used?
LAMICTAL CD contains lamotrigine, an anticonvulsant and mood-stabilizing active ingredient. The formulation is a chewable/dispersible tablet that can be chewed, dispersed in water or swallowed whole, depending on the product labeling and strength.
| Attribute |
LAMICTAL CD |
| Active ingredient |
Lamotrigine |
| Original manufacturer |
GlaxoSmithKline |
| Formulation |
Chewable/dispersible tablet |
| Main indications |
Epilepsy and bipolar I disorder maintenance treatment |
| U.S. strengths historically marketed |
2 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg |
| U.S. regulatory application |
NDA 020241 for LAMICTAL products |
| Current commercial status |
Mature branded product with generic competition |
| Biosimilar exposure |
None; lamotrigine is a small-molecule drug |
| Primary competitive threat |
Generic lamotrigine tablets and chewable/dispersible tablets |
The formulation has clinical utility for patients who have difficulty swallowing conventional tablets, including pediatric patients. Its commercial market is narrower than the market for standard lamotrigine tablets because most adult patients can use tablets or orally disintegrating formulations.
What is the FDA regulatory status of LAMICTAL CD?
The FDA approved LAMICTAL for partial seizures and certain generalized seizures, with later approval for maintenance treatment of bipolar I disorder in adults. The FDA labeling includes titration instructions because rapid dose escalation increases the risk of serious skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis (FDA, 2024a).
LAMICTAL CD is regulated as a conventional small-molecule prescription drug. It does not qualify for biologic exclusivity, interchangeable biosimilar treatment, or biologic patent protections.
What is the Orange Book status of LAMICTAL CD?
The FDA Orange Book historically listed LAMICTAL as the reference drug for lamotrigine products. The relevant branded product listings have been subject to changes in marketing status as GSK discontinued or modified individual presentations. Generic approvals remain tied to the reference product and its dosage-form specifications (FDA, 2024b).
The current commercial significance of the Orange Book listing is limited because:
- The core lamotrigine compound patents expired years ago.
- Generic manufacturers have obtained approvals for several lamotrigine dosage forms.
- No material period of pediatric, orphan, or new chemical entity exclusivity remains.
- The brand does not have a practical regulatory barrier preventing generic substitution where state law and pharmacy practice permit it.
What patents protect LAMICTAL CD?
The original lamotrigine patent estate is expired. The key composition-of-matter protection for lamotrigine did not survive into the current market period, and generic entry occurred many years ago.
| Protection category |
Current position |
| Lamotrigine composition patent |
Expired |
| Original LAMICTAL formulation protection |
Expired or commercially ineffective |
| Method-of-use patents |
Expired, invalidated, or not commercially blocking |
| Pediatric exclusivity |
Expired |
| New chemical entity exclusivity |
Expired |
| Current U.S. patent barrier |
None material |
| Current generic-entry restriction |
None material |
The relevant patent risk is therefore not a blocking patent risk. It is a product-quality and manufacturing risk involving dosage-form performance, dissolution, stability, taste, and reliable dispersion.
What formulations were protected by LAMICTAL patents?
The original LAMICTAL estate covered lamotrigine and pharmaceutical compositions containing the active ingredient. Later product development supported multiple delivery formats, including conventional tablets, chewable/dispersible tablets, and orally disintegrating tablets.
Formulation differences remain commercially relevant even after patent expiry. A generic manufacturer must demonstrate pharmaceutical equivalence and bioequivalence for the dosage form it seeks to market. For a chewable/dispersible product, technical requirements can include:
- Consistent drug content across the tablet.
- Rapid and reproducible dispersion.
- Acceptable taste and mouthfeel.
- Stable performance over the labeled shelf life.
- Appropriate dissolution behavior.
- Manufacturing controls that limit dose variability.
These attributes can create development and supply-chain barriers, but they do not create durable exclusivity comparable to a valid composition patent.
When did LAMICTAL CD lose exclusivity?
LAMICTAL lost meaningful U.S. market exclusivity when generic lamotrigine products entered after expiration of the core patent protections. Generic competition for lamotrigine became established in the mid-2000s, and branded LAMICTAL revenue subsequently declined.
The key exclusivity timeline is:
| Period |
Event |
Commercial effect |
| 1990s |
LAMICTAL launched and expanded into epilepsy treatment |
Brand-led market formation |
| 2003 |
FDA approved LAMICTAL for bipolar I maintenance treatment |
Expanded branded demand |
| Mid-2000s |
Generic lamotrigine entry began |
Rapid price and share pressure |
| 2010s |
Multiple generic dosage forms became available |
Brand differentiation narrowed |
| 2020s |
Mature generic market |
Low branded growth and limited pricing power |
LAMICTAL CD therefore does not have a credible future exclusivity event that would materially change its market position.
How strong is the patent estate for LAMICTAL CD?
The patent estate is commercially weak for current U.S. market purposes. Its historical value was substantial because lamotrigine was protected during the period when LAMICTAL established its epilepsy and bipolar franchise. Its present value is primarily defensive and historical.
Patent-strength assessment
| Factor |
Assessment |
| Composition-of-matter protection |
Very weak; expired |
| Formulation protection |
Weak; no known current blocking position |
| Method-of-use protection |
Weak; principal indications are long established |
| Generic blocking power |
None material |
| Litigation leverage |
Low |
| Licensing leverage |
Low |
| Manufacturing know-how value |
Moderate for quality and supply reliability |
| Brand recognition |
Still meaningful in some clinical settings |
| Pricing power |
Low |
A generic manufacturer does not need to overcome an active LAMICTAL CD patent barrier to enter the market. The main obstacles are FDA approval, manufacturing validation, pharmacokinetic equivalence, supply reliability, and payer access.
Which companies challenge LAMICTAL CD in the generic market?
The lamotrigine market includes generic products from major multinational and specialty-generic manufacturers, including Teva, Sandoz, Viatris, Dr. Reddy's Laboratories, Zydus and other approved ANDA sponsors. The competitive field varies by dosage form and national market.
Competition is strongest in standard tablets. Chewable/dispersible products have a smaller supplier base because the addressable population is narrower and formulation development is more specialized.
Generic competition by dosage form
| Dosage form |
Competitive intensity |
Commercial observation |
| Immediate-release tablets |
High |
Broad generic supply and substantial price erosion |
| Chewable/dispersible tablets |
Moderate |
Fewer suppliers and smaller patient segment |
| Orally disintegrating tablets |
Moderate |
Differentiated administration but generic competition |
| Extended-release tablets |
Moderate |
Separate formulation and approval requirements |
| Oral suspension or compounded forms |
Low to moderate |
Niche use and pharmacy-dependent supply |
The competitive landscape is therefore fragmented rather than concentrated around one direct LAMICTAL CD successor.
What generic entry risks exist for LAMICTAL CD?
Generic entry risk is already realized rather than prospective. The relevant business question is whether generic competition will continue to erode brand demand or whether the product can retain a specialized niche.
The principal risks are:
- Generic substitution at the pharmacy level.
- Formulary exclusion of branded lamotrigine.
- Price competition among ANDA sponsors.
- Conversion from LAMICTAL CD to generic chewable/dispersible products.
- Conversion to conventional tablets when patients can swallow them.
- Use of alternative lamotrigine dosage forms with lower acquisition costs.
Clinical switching can be managed carefully because lamotrigine dosing is titrated and treatment continuity matters. That consideration may preserve some prescriber preference for the brand, but it does not generally prevent payer-led substitution.
What is the financial trajectory of LAMICTAL CD?
GSK does not report LAMICTAL CD as a separate revenue line. Historical disclosures generally aggregate sales under LAMICTAL or broader established pharmaceutical categories. The product’s standalone financial trajectory therefore cannot be measured from public company reporting with precision.
The direction of value is clear:
| Financial phase |
Revenue profile |
Margin profile |
| Pre-generic period |
Strong brand growth |
High branded-pharmaceutical margin |
| Initial generic entry |
Rapid revenue decline |
Margin compression |
| Mature generic period |
Low and declining brand sales |
Reduced strategic importance |
| Current market |
Limited standalone brand value |
Value concentrated in generic supply |
GSK’s financial reporting treats LAMICTAL as part of its established medicines portfolio rather than as a growth asset. The absence of a separately disclosed current revenue figure indicates that LAMICTAL CD is not material enough to be reported independently in the company’s principal operating disclosures (GSK, 2005; GSK, 2023).
What is the revenue exposure for GSK?
GSK’s revenue exposure to LAMICTAL CD is likely limited relative to its vaccines, respiratory products and newer specialty medicines. The product’s commercial contribution is constrained by:
- Longstanding generic competition.
- Lack of current exclusivity.
- Limited differentiation between brand and approved generic products.
- A relatively narrow patient segment for the chewable/dispersible presentation.
- Reduced strategic focus on mature small-molecule brands.
Any remaining sales are more likely to reflect brand loyalty, institutional purchasing, patient-specific tolerability, or availability preferences than patent-supported pricing power.
Are there biosimilar risks for LAMICTAL CD?
No. Lamotrigine is a synthetic small-molecule active ingredient, not a biologic. The appropriate competitive framework is generic substitution, not biosimilar interchangeability.
The relevant regulatory pathway is the abbreviated new drug application under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. Generic manufacturers must show pharmaceutical equivalence and bioequivalence to the reference product. Biosimilar approval under the Public Health Service Act does not apply.
What litigation and Paragraph IV challenges affect LAMICTAL CD?
The principal Paragraph IV risk occurred during the original generic-entry period, when generic applicants challenged or sought to avoid the remaining lamotrigine patent protections. That period has passed.
There is no current commercial indication that a live Paragraph IV campaign could materially delay generic lamotrigine entry. The market is already populated by approved generic products.
| Litigation issue |
Current commercial relevance |
| Historical patent challenges |
Relevant to initial generic entry |
| Current Paragraph IV blockade |
None material |
| Brand-versus-generic patent dispute |
Low |
| Product liability exposure |
Possible but separate from exclusivity |
| Manufacturing litigation |
Could affect individual suppliers, not the molecule-wide market |
| Settlement agreements |
No current settlement is known to preserve broad LAMICTAL CD exclusivity |
A generic manufacturer could still face ordinary litigation involving labeling, manufacturing, trade dress, regulatory compliance or supply contracts. Those disputes would not restore market exclusivity for the brand.
Were there licensing deals involving LAMICTAL CD?
LAMICTAL was developed and commercialized within GSK’s historical pharmaceutical operations. Public disclosures do not indicate a current licensing structure that materially supports LAMICTAL CD revenue or protects the product from generic competition.
Any historical collaboration or regional commercialization arrangements would have limited present economic significance because the relevant patents have expired and generic products are widely available.
How does LAMICTAL CD compare with competing lamotrigine products?
| Product category |
Patient need |
Brand advantage |
Generic threat |
Commercial outlook |
| LAMICTAL CD |
Chewable or dispersible administration |
Familiarity and historical physician confidence |
High |
Mature niche |
| Generic lamotrigine chewable/dispersible |
Same administration benefit |
Lower price |
Competes directly with brand |
Stable or growing share |
| Standard lamotrigine tablet |
Broad adult use |
Lower cost and wide availability |
Already genericized |
Largest volume segment |
| Lamotrigine ODT |
Swallowing convenience |
Formulation differentiation |
Moderate to high |
Niche growth |
| Lamotrigine extended release |
Reduced dosing frequency |
Convenience |
Generic competition |
Separate but established segment |
LAMICTAL CD’s strongest remaining advantage is formulation familiarity. Its weakest point is the absence of price or exclusivity protection.
What generic launch scenarios exist for LAMICTAL CD?
Three scenarios define the remaining market:
Continued brand erosion
Generic manufacturers maintain supply across key strengths and pharmacies substitute generic products. Brand sales continue to decline, with LAMICTAL CD retained mainly for selected patients.
Stable niche demand
Some patients remain on the branded chewable/dispersible product because of tolerability, administration preference or physician continuity. Brand volume stabilizes at a low level without meaningful price expansion.
Supply-driven generic volatility
A manufacturing interruption or shortage affects one or more generic suppliers. Pharmacies temporarily source alternative products, potentially supporting short-term branded demand. This would be a supply event, not a patent-driven recovery.
The base case is continued generic dominance with limited branded growth.
What geographic coverage remains for LAMICTAL CD?
The product’s commercial status varies by country. Patent expiration, generic approval, reimbursement rules and brand discontinuation decisions are jurisdiction-specific. In major markets, including the United States and Europe, lamotrigine is broadly genericized.
Geographic value is greatest where:
- Generic competition is limited.
- The brand remains actively promoted or reimbursed.
- Chewable or dispersible formulations have limited alternatives.
- Regulatory approval for competing dosage forms is slower.
- Distribution relationships favor the originator.
Geographic coverage does not change the fundamental conclusion that LAMICTAL CD lacks a material global exclusivity position.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are more relevant than patent barriers. A supplier must reliably produce a dose-sensitive formulation that meets FDA or equivalent regulatory standards. The main barriers include:
- Taste masking and patient acceptability.
- Uniformity across low-dose tablets.
- Dispersion performance.
- Stability and packaging.
- Scale-up validation.
- Consistent raw-material supply.
- Regulatory documentation for each strength and dosage form.
These barriers may reduce the number of suppliers for a particular presentation. They do not support the pricing power associated with an active patent estate.
Key Takeaways
- LAMICTAL CD is the chewable/dispersible formulation of lamotrigine.
- Its core patents and regulatory exclusivities have expired.
- Generic lamotrigine competition has existed since the mid-2000s.
- No current patent barrier materially limits generic entry in the United States.
- GSK does not disclose standalone LAMICTAL CD revenue.
- The product has limited remaining brand value and no credible high-growth financial trajectory.
- The chewable/dispersible format may retain a niche among patients with swallowing difficulties.
- Manufacturing quality, supply reliability and formulation performance are more important than intellectual property.
- Biosimilar risk is irrelevant because lamotrigine is a small molecule.
- The commercial base case is stable generic dominance and low branded revenue.
FAQs
Is LAMICTAL CD still commercially available?
Availability depends on country, strength and distributor inventory. Generic lamotrigine chewable/dispersible alternatives are generally more important to current market supply than the originator brand.
Is generic lamotrigine the same as LAMICTAL CD?
Approved generic products must meet applicable pharmaceutical-equivalence and bioequivalence requirements. The inactive ingredients, tablet characteristics and patient experience can differ by manufacturer.
Does LAMICTAL CD have patent protection in the United States?
No material unexpired patent protection is known to block generic lamotrigine entry for the core product or its established chewable/dispersible presentation.
Can a pharmacy automatically substitute generic lamotrigine for LAMICTAL CD?
Substitution depends on the product’s therapeutic-equivalence rating, state law, payer rules and the prescriber’s instructions. The pharmacy’s substitution authority can vary by jurisdiction.
Does LAMICTAL CD have investment value as a branded product?
Its investment value is limited. The product has mature demand, extensive generic competition, no meaningful remaining exclusivity and no separately disclosed growth trajectory. Its principal commercial value is residual niche demand and manufacturing familiarity.
References
-
GlaxoSmithKline. (2005). Annual report 2004. GlaxoSmithKline plc.
-
GlaxoSmithKline. (2023). Annual report 2022. GSK plc.
-
U.S. Food and Drug Administration. (2024a). LAMICTAL (lamotrigine) prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
